| Article 95 Published on December 19, 2016 |
About Implantable Continuous Glucose Monitor
A study result shows implantable type continuous glucose monitoring (CGM) systems are accurate and safe to use compared to transcutaneous type continuous glucose monitoring (CGM) systems. Implantable type continuous glucose monitoring (CGM) systems require minor surgical procedure but usage benefits with them are
- Implantable type continuous glucose monitoring (CGM) systems do not require frequent sensor insertions through the skin
- Periodic sensor replacement not required
- No more sensor damage risk
- The transmitter can be removed easily
Researchers evaluated the performance of the Eversense (Senseonics Inc) implantable CGM systems in 71 individuals with type 1 (T1D) and type 2 diabetes (T2D). Results show improvements in HbA1c levels. The study findings were published in Diabetes Care.
Risks To Bone Loss
Researchers say body bone loss is associated with diabetes and osteoporosis is the consequence of diabetes. Both diabetes and osteoporosis conditions increases as individual ages. Diabetes effects are as follows
- In type 1 diabetes (T1D), bones are affected by bone mineral density loss and bones weaken. These conditions lead to osteoporosis.
- In type 2 diabetes (T2D), no bone mineral density loss but bone mass density levels will be above average levels. Many of the T2D patients are obese and the extra weight increases bone weakening and bone loss as the patient ages. An earlier study show patients with type 2 diabetes are at higher risk of bone fractures even though they are with higher bone mineral density.
Other risk factors for the deterioration of bones and osteoporosis are
Tips to prevent osteoporosis and diabetes are
- Perform regular exercise to build muscle and reduce fat. Muscle helps an individual in building strong bones
- Eat calcium and vitamin D rich food
- Avoid alcohol consumption
- Avoid smoking
- Take specific medications to build strong bones
Researchers say the health of bones can be improved with exercise if the blood sugar levels are not at elevated levels (hyperglycemia). Senior author of the study is Sundeep Khosla.
Sensogram Technologies is a global leader in wireless and wearable devices. The company successfully completed three pilot clinical studies of the SensoSCAN wearable device. Sensogram President Ernie Ianace says the company is planning to conduct further studies by including testing the product with blood oxygen saturation, heartbeat rate and respiration rate parameters. Features of SensoSCAN product are
- A non-invasive device
- A cuffless device
- A device that can be worn on the finger
The device reads blood pressure of an individual in real-time with optical scanning technology and sends real-time data to the cloud (wireless communication). Needed individuals can access the real-time data through mobile App. The company says this technology can be used in wearable devices to be used in clinical care, sports, PERS (Public Employees Retirement System), military etc. The company already started implementing the new technology and product. The product will be available in health and wellness applications in the United States market during January 2017.
About Meizus H1 Wearable Device
According to media reports, Chinese consumer electronics company Meizu introduced the Fitbit-like device at a fraction of cost. A touchscreen display of the Meizus H1 product contains a hidden OLED screen. The OLED screen of the product displays
- Current step count
- Heart rate
- Number of calories burned
Features of the Meizus H1 product are
- Auto sleep tracking
- Wearable alarm clock
- Can receive calls and text messages
- Enable user to connect to the caller
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.